The Role of SF2 in Prostate Cancer Progression
Abstract
Prostate cancer (a leading cause of male mortality) development and progression is dependent upon androgen and androgen receptor (AR) signaling. Current therapies target androgen production and/or AR signaling. Evidence suggests that AR in some tumors may escape therapy through mechanisms that likely involve splicing. Purpose: To better understand splicing during prostate cancer development or progression. Scope: As outlined in the proposal (and published) observations suggest that the splicing factor (SF2) may contribute to prostate cancer in part through altered D-cyclin splicing. Findings to date: have been made on determining the status, using a recently developed immunohistochemical approach, of SF2 in human prostate cancer specimens. Progress has also been made on determining the biological relevance in prostate cancer-derived cell model systems with altered levels of SF2 that mimic human disease. Simultaneous efforts have been made to develop targeted knockdown of SF2 to decipher the SF2-mediated splicing repertoire in prostate cancer.
Document Details
- Document Type
- Technical Report
- Publication Date
- Apr 01, 2012
- Accession Number
- ADA562121
Entities
People
- Betty Diamond
- Clay Comstock
Organizations
- Thomas Jefferson University